Deutsche Bank Aktiengesellschaft began coverage on shares of Smith & Nephew (NYSE:SNN – Free Report) in a research report sent to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued a buy rating on the medical equipment provider’s stock.
Other analysts also recently issued research reports about the company. StockNews.com downgraded Smith & Nephew from a strong-buy rating to a buy rating in a research note on Monday, May 13th. UBS Group raised Smith & Nephew from a neutral rating to a buy rating in a research note on Wednesday, June 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Smith & Nephew currently has a consensus rating of Moderate Buy.
Read Our Latest Research Report on SNN
Smith & Nephew Trading Down 0.0 %
Institutional Investors Weigh In On Smith & Nephew
A number of institutional investors and hedge funds have recently modified their holdings of SNN. CWM LLC raised its position in shares of Smith & Nephew by 68.6% during the fourth quarter. CWM LLC now owns 954 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 388 shares during the period. Spire Wealth Management raised its position in shares of Smith & Nephew by 224.3% during the fourth quarter. Spire Wealth Management now owns 1,015 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 702 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Smith & Nephew by 75.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,227 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 526 shares during the period. Parallel Advisors LLC raised its position in shares of Smith & Nephew by 150.9% during the fourth quarter. Parallel Advisors LLC now owns 1,533 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 922 shares during the period. Finally, Mather Group LLC. raised its position in shares of Smith & Nephew by 9,735.3% during the second quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 1,655 shares during the period. 25.64% of the stock is owned by institutional investors and hedge funds.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Further Reading
- Five stocks we like better than Smith & Nephew
- What is the FTSE 100 index?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Basic Materials Stocks Investing
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.